As Q1 comes to a close, there is a critical window that most aesthetic practice owners overlook. This is the moment where the year either gets recalibrated—or quietly derails.

Let’s call it like it is—the industry is oversaturated. Every city is packed with injectors fighting for the same patients. The practices that survive the next five years won’t be the ones doing the most treatments; they’ll be the ones offering the most meaningful treatments.

The aesthetic industry has always been built on innovation. New technologies, new injectables, new regenerative biologics — every few months, something “game-changing” hits your inbox or trade show floor. But with that opportunity comes risk. Specifically: the risk of using products off-label — that is, outside of their FDA-approved indications. It’s not illegal to do so, but it’s not without boundaries either.